Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/173849
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sancho, Juan Manuel | - |
dc.contributor.author | Fernández Alvarez, Rubén | - |
dc.contributor.author | Gual Capllonch, Francisco | - |
dc.contributor.author | González García, Esther | - |
dc.contributor.author | Grande, Carlos | - |
dc.contributor.author | Gutiérrez, Norma | - |
dc.contributor.author | Peñarrubia, María Jesús | - |
dc.contributor.author | Batlle López, Ana | - |
dc.contributor.author | González Barca, Eva | - |
dc.contributor.author | Guinea, José María | - |
dc.contributor.author | Gimeno, Eva | - |
dc.contributor.author | Peñalver, Francisco J. | - |
dc.contributor.author | Fuertes, Miguel | - |
dc.contributor.author | Bastos, Mariana | - |
dc.contributor.author | Hernández Rivas, José Ángel | - |
dc.contributor.author | Moraleda, José María | - |
dc.contributor.author | García, Olga | - |
dc.contributor.author | Sorigué, Marc | - |
dc.contributor.author | Martin, Alejandro | - |
dc.date.accessioned | 2021-02-11T08:39:54Z | - |
dc.date.available | 2021-02-11T08:39:54Z | - |
dc.date.issued | 2021-01-25 | - |
dc.identifier.uri | http://hdl.handle.net/2445/173849 | - |
dc.description.abstract | The use of non-pegylated liposomal doxorubicin (Myocet®) in diffuse large B-cell lymphoma (DLBCL) has been investigated in retrospective and single-arm prospective studies. This was a prospective phase 2 trial of DLBCL patients ≥60 years old with left ventricular ejection fraction (LVEF) ≥55% randomized to standard R-CHOP or investigational R-COMP (with Myocet® instead of conventional doxorubicin). The primary end point was to evaluate the differences in subclinical cardiotoxicity, defined as decrease in LVEF to <55% at the end of treatment. Secondary objectives were efficacy, safety, and variations of troponin and N-terminal pro-B-type natriuretic peptide (NT-proBNP) and LVEF along follow-up. Ninety patients were included, 45 in each group. No differences were observed in the percentage of patients with LVEF <55% at end of treatment (11% in R-CHOP arm vs. 7% in R-COMP arm, p = 0.697) or at 4 months (10% vs. 6%, respectively, p = 0.667) and 12 months (8% vs. 7%, respectively, p = 1). However, a higher percentage of R-CHOP compared with R-COMP patients showed increased troponin levels in cycle 6 (100% vs. 63%, p = 0.001) and at 1 month after treatment (88% vs. 56%, respectively, p = 0.015). Cardiovascular adverse events were seen in five R-CHOP patients (nine episodes, four grade ≥3) and in four R-COMP patients (five episodes, all grade 1–2). No significant differences in efficacy were observed. In conclusion, R-COMP is a feasible immunochemotherapy schedule for DLBCL patients ≥60 years, with similar efficacy to R-CHOP. However, the use of non-pegylated doxorubicin instead of conventional doxorubicin was not associated with less early cardiotoxicity, although some reduced cardiac safety signals were observed. Trial registration: ClinicalTrials.gov Identifier: NCT02012088. | - |
dc.format.extent | 13 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Wiley | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1002/cam4.3730 | - |
dc.relation.ispartof | Cancer Medicine, 2021 | - |
dc.relation.uri | https://doi.org/10.1002/cam4.3730 | - |
dc.rights | cc by (c) Sancho et al., 2021 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | - |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Limfomes | - |
dc.subject.classification | Cèl·lules B | - |
dc.subject.other | Lymphomas | - |
dc.subject.other | B cells | - |
dc.title | R‐COMP versus R‐CHOP as first‐line therapy for diffuse large B‐cell lymphoma in patients ≥60 years: Results of a randomized phase 2 study from the Spanish GELTAMO group | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2021-02-11T07:29:24Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 33492774 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
cam4.3730.pdf | 514.05 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License